Chia Tai keeps the TGF-β faith
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
Global data are in the same ballpark as Chinese results presented earlier this year.
It’s a new term for biotech and its investors.
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
PD-(L)1 x VEGF bispecifics prove a big draw.
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.